Drug · CHEMBL760
ANAGRELIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ANAGRELIDE. Drugs and targets, record CHEMBL760. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL760
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 4 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PDE3A | Phosphodiesterase 3 | Phosphodiesterase 3 inhibitor | INHIBITOR | https://conductscience.org/library/genes/5139 |
| PDE3B | Phosphodiesterase 3 | Phosphodiesterase 3 inhibitor | INHIBITOR | https://conductscience.org/library/genes/5140 |
Source ChEMBL
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| essential thrombocythemia | Approval | EMA Human Drugs | 12 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005029 |
| Thrombocytosis | Approval | TTD | 2 | 1 | https://conductscience.org/library/drugs?q=HP_0001894 |
| acquired polycythemia vera | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0009891 |
| neoplasm | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0005070 |
Source Open Targets
Trials14
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00202644 | A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients | Phase 4 | 150 | 2018-01-24 | anagrelide | Its name | ClinicalTrials.gov |
| NCT02038036 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | Phase 3 | 149 | 2021-07-20 | best available therapy | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01552928 | Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers | Phase 1 | 60 | 2014-01-10 | anagrelide | Its name | ClinicalTrials.gov |
| NCT01214915 | Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia | Phase 3 | 53 | 2013-09-25 | anagrelide | Its name | ClinicalTrials.gov |
| NCT03866434 | Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants | Phase 1 | 20 | 2020-04-24 | anagrelide | Its name | ClinicalTrials.gov |
| NCT03123588 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | Phase 2 | 12 | 2021-11-19 | anagrelide | Its name | ClinicalTrials.gov |
| NCT04285086 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Phase 3 | 174 | anagrelide | Its name | ClinicalTrials.gov | |
| NCT01230775 | Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia | Phase 3 | 146 | anagrelide | Its name | ClinicalTrials.gov | |
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia | Phase 3 | 106 | anagrelide | Its name | ClinicalTrials.gov | |
| NCT03232177 | Anagre Cap. in Patients With High-Risk Essential Thrombocythemia | Phase 4 | 70 | anagrelide | Its name | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anagrelide vs Hydroxyurea: serious adverse events | 17 of 76 | 13 of 70 | 146 | NCT00202644 | Trial comparisons |
| Anagrelide vs Hydroxyurea: Number of Participants With Thrombotic and Haemorrhagic Events | 30 of 73 | 16 of 68 | 141 | NCT00202644 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib Placebo: deaths from any cause | 0 of 5 | 0 of 6 | 11 | NCT03123588 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib PLacebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 of 5 | 4 of 6 | 11 | NCT03123588 | Trial comparisons |
| Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib Placebo: serious adverse events | 0 of 5 | 1 of 6 | 11 | NCT03123588 | Trial comparisons |
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL760
GET https://conductscience.org/api/drugs/v1/CHEMBL760/targets